atopaxar
Small moleculeexperimental
Clinical trial activity
6 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2007 (NCT00312052)
Timeline
Indications
Mechanism of action
- Proteinase-activated receptor 1ANTAGONIST
F2R antagonist
Chemistry & pharmacology
Loading structure…
SMILES
CCOc1cc2c(c(F)c1OCC)C(=N)N(CC(=O)c1cc(N3CCOCC3)c(OC)c(C(C)(C)C)c1)C2- Mol. weight
- 527.64 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2103856 ↗
- ChEMBLCHEMBL2105699 ↗
Also known as
- atopaxar
- atopaxar
- atopaxar
- atopaxar
- atopaxar hydrobromide
- atopaxar hydrobromide
- e5555
- e5555
- e5555
- e 5555
- e-5555
- e5555 cpd
- er-172594-00
- er-172594-00
- er-172594-06
- er-172594-06
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01241669 | Phase 1 | Oct 1, 2010 | Eisai |
| NCT01261156 | Phase 1 | Oct 1, 2010 | Eisai |
| NCT00619164 | Phase 2 | Nov 1, 2007 | Eisai |
| NCT00540670 | Phase 2 | Oct 1, 2007 | Eisai |
| NCT00548587 | Phase 2 | Oct 1, 2007 | Eisai |
| NCT00312052 | Phase 2 | Sep 1, 2007 | Eisai |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eisai | For profit | 6 | 6 | 2 | 2007 |
1 organizations
Page 1 / 1